Genetic factors influencing cytarabine therapy

Pharmacogenomics

Volumn 10, Issue 10, 2009, Pages 1657-1674

  Lamba, Jatinder K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cytarabine; Cytidine deaminase; Deoxycytidine kinase; Nucleoside analog; Pharmacogenetics; SNPs

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 5' NUCLEOTIDASE; ABC TRANSPORTER; CLADRIBINE; CYTARABINE; CYTIDINE DEAMINASE; CYTIDINE TRIPHOSPHATE SYNTHASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; BLOOD TOXICITY; CANCER SURVIVAL; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; GENE EXPRESSION; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

5'-NUCLEOTIDASE; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FORECASTING; GENETIC VARIATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NUCLEOSIDE DEAMINASES; PHARMACOGENETICS; RIBONUCLEOTIDE REDUCTASES;

ARA;

EID: 70649100419     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.118     Document Type: Review

References (110)

1. Wang JJ, Selawry OS, Vietti TJ, Bodey GP: Prolonged infusion of arabinosyl cytosine in childhood leukemia. Cancer 25, 6 (1970).
2. Creutzig U, Berthold F, Boos J et al.: [Improved treatment results in children with AML: Results of study AML-BFM 93]. Klin. Padiatr. 213, 175-185 (2001).
3. Krance RA, Hurwitz CA, Head DR et al.: Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J. Clin. Oncol. 19, 2804-2811 (2001).
4. Capizzi RL, Yang JL, Rathmell JP et al.: Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Semin. Oncol. 12, 65-74 (1985).
5. Galmarini CM, Mackey JR, Dumontet C: Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15, 875-890 (2001).
6. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR: Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J. Clin. Invest. 75, 632-642 (1985). (Pubitemid 15142074)
7. Weick JK, Kopecky KJ, Appelbaum FR et al.: A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88, 2841-2851 (1996).
8. Capizzi RL, Yang JL, Cheng E et al.: Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J. Clin. Oncol. 1, 763-771 (1983). (Pubitemid 14167250)
9. Kufe DW, Major PP, Egan EM, Beardsley GP: Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem. 255, 8997-18900 (1980).
10. Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW: Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl Acad. Sci. USA 78, 3235-3239 (1981).
11. Raza A, Gezer S, Anderson J et al.: Relationship of [3H] Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp. Hematol. 20, 1194-1200 (1992).
12. Gandhi V, Estey E, Keating MJ, Plunkett W: Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk. Lymphoma 10(Suppl.), 109-114 (1993). (Pubitemid 23120975)
13. Avramis VI, Wiersma S, Krailo MD et al.: Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin. Cancer Res. 4, 45-52 (1998). (Pubitemid 28062876)
14. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM: The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer 103, 1985-1995 (2005).
15. Gandhi V, Plunkett W: Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother. Pharmacol. 31, 11-17 (1992).
16. Kufe DW, Munroe D, Herrick D, Egan E, Spriggs D: Effects of 1-β-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol. Pharmacol. 26, 128-134 (1984). (Pubitemid 14035234)
17. Chou TC, Arlin Z, Clarkson BD, Phillips FS: Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res. 37, 3561-3570 (1977). (Pubitemid 8198413)
18. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin. Oncol. 12, 20-30 (1985). ■ Demonstrates the relationship of intracellular ara-cytidine-5-primetri-phosphate (ara-CTP) levels with treatment response. (Pubitemid 15063578)
19. Momparler RL, Fischer GA: Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J. Biol. Chem. 243, 4298-4304 (1968).
20. Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE: The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat. Res. 112, 27-47 (2002).
21. Sundaram M, Yao SY, Ingram JC et al.: Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J. Biol. Chem. 276, 45270-45275 (2001). (Pubitemid 37391322)
22. Hubeek I, Peters GJ, Broekhuizen AJ et al.: Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J. Clin. Pathol. 58, 695-699 (2005). (Pubitemid 40956821)
23. Hubeek I, Stam RW, Peters GJ et al.: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 93, 1388-1394 (2005). ■ Demonstrates the relationship between hENT1 mRNA and response to ara-C in pediatric acute myeloid leukemia. (Pubitemid 41752866)
24. Galmarini CM, Thomas X, Calvo F et al.: In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 117, 860-868 (2002). (Pubitemid 34639247)
25. Stam RW, den Boer ML, Meijerink JP et al.: Differential mRNA expression of ara-C-metabolizing enzymes explains ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101, 1270-1276 (2003).
26. Gati WP, Paterson AR, Belch AR et al.: Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk. Lymphoma 32, 45-54 (1998).
27. Gati WP, Paterson AR, Larratt LM, Turner AR, Belch AR: Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90, 346-353 (1997).
28. Giovannetti E, Del TM, Mey V et al.: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66, 3928-3935 (2006).
29. Michalski CW, Erkan M, Sauliunaite D et al.: Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br. J. Cancer 995, 760-767 (2008).
30. Farrell JJ, Elsaleh H, Garcia M et al.: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1), 187-195 (2009).
31. Osato DH, Huang CC, Kawamoto M et al.: Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13, 297-301 (2003). ■ First report on functional characterization of hENT1 genetic variants. (Pubitemid 36583998)
32. Chaudary N, Naydenova Z, Shuralyova I, Coe IR: Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc. Res. 61, 780-788 (2004). (Pubitemid 38249477)
33. Eltzschig HK, Abdulla P, Hoffman E et al.: HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med.. 202, 1493-1505 (2005). (Pubitemid 41746596)
34. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE: Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet. Genomics 16, 315-320 (2006).
35. Kim SR, Saito Y, Maekawa K et al.: Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). Drug Metab. Pharmacokinet.21, 248-256 (2006).
36. Bhalla K, Nayak R, Grant S: Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D- arabinofuranosylcytosine. Cancer Res. 44, 5029-5037 (1984). (Pubitemid 15204459)
37. Dumontet C, Fabianowska-Majewska K, Mantincic D et al.: Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br. J. Haematol. 106, 78-85 (1999). (Pubitemid 29343530)
38. Verhoef V, Sarup J, Fridland A: Identification of the mechanism of activation of 9-β-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases. Cancer Res. 41, 4478-4483 (1981). (Pubitemid 12201361)
39. Hapke DM, Stegmann AP, Mitchell BS: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56, 2343-2347 (1996).
40. Stegmann AP, Honders WH, Willemze R, Ruiz van Haperen VW, Landegent JE: Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Blood 85, 1188-1194 (1995).
41. Kakihara T, Fukuda T, Tanaka A et al.: Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk. Lymphoma 31, 405-409 (1998). (Pubitemid 29033962)
42. van der Wilt CL, Kroep JR, Loves WJ et al.: Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur. J. Cancer 39, 691-697 (2003).
43. Lotfi K, Karlsson K, Fyrberg A et al.: The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. Biochem. Pharmacol. 71, 882-890 (2006). (Pubitemid 43208845)
44. Galmarini CM, Thomas X, Calvo F et al.: Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res. 26, 621-629 (2002). (Pubitemid 34465699)
45. Kroep JR, Loves WJ, van der Wilt CL et al.: Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1, 371-376 (2002).
46. Shi JY, Shi ZZ, Zhang SJ et al.: Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14, 759-768 (2004). ■■ First report on deoxycytidine kinase genetic variants in a Chinese population.
47. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH: Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur. J. Clin. Pharmacol. 62, 681-684 (2006). (Pubitemid 44127999)
48. Lamba JK, Crews K, Pounds S et al.: Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther. 323, 935-945 (2007). ■ First report on deoxycytidine kinase genetic variants and association with leukemic cell ara-CTP levels in pediatric acute myeloid leukemia patients. (Pubitemid 350146062)
49. Kocabas NA, Aksoy P, Pelleymounter LL et al.: Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab. Dispos. 36, 1951-1959 (2008).
50. Kim SR, Saito Y, Maekawa K et al.: Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab. Pharmacokinet.23, 379-384 (2008).
51. Bianchi V, Pontis E, Reichard P: Interrelations between substrate cycles and de novo synthesis of pyrimidine deoxyribonucleoside triphosphates in 3T6 cells. Proc. Natl Acad. Sci. USA 83, 986-990 (1986). (Pubitemid 16086398)
52. Hunsucker SA, Mitchell BS, Spychala J: The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107, 1-30 (2005).
53. Galmarini CM, Cros E, Thomas X, Jordheim L, Dumontet C: The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica 90, 1699-1701 (2005). (Pubitemid 41814998)
54. Seve P, Mackey JR, Isaac S et al.: cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 49, 363-370 (2005). ■ Demonstrates the association of cN-II (NT5C2) mRNA expression with gemcitabine response. (Pubitemid 41139149)
55. Yamauchi T, Negoro E, Kishi S et al.: Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem. Pharmacol. 77, 1780-1786 (2009).
56. Grant, S: Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. 72, 197-233 (1998).
57. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG: Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5, 226-243 (2005).
58. Jahns-Streubel G, Reuter C, uf der LU et al.: Activity of thymidine kinase and of polymerase α as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 90, 1968-1976 (1997).
59. Schroder JK, Kirch C, Seeber S, Schutte J: Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br. J. Haematol. 103, 1096-1103 (1998). (Pubitemid 29012650)
60. Schroder JK, Seidelmann M, Kirch HC, Seeber S, Schutte J: Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro. Leuk. Res. 22, 619-624 (1998). (Pubitemid 28327465)
61. Giovannetti E, Mey V, Loni L et al.: Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol. Res. 55, 343-349 (2007). (Pubitemid 46518163)
62. Mercier C, Dupuis C, Blesius A et al.: Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother. Pharmacol. 63, 1177-1180 (2009).
63. Yue L, Saikawa Y, Ota K et al.: A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13, 29-38 (2003). ■ First study to report cytidine deaminase polymorphisms in a Japanese population. (Pubitemid 36135684)
64. Gilbert JA, Salavaggione OE, Ji Y et al.: Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12, 1794 - 1803 (2006). ■ First report on sequencing and identification of cytidine deaminase and deoxycytidylate deaminase polymorphisms in multiple ethnic panels.
65. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J: Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp. Hematol. 26, 421-425 (1998). (Pubitemid 28198740)
66. Bhatla D, Gerbing RB, Alonzo TA et al.: Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144, 388-394 (2009).
67. Giovannetti E, Laan AC, Vasile E et al.: Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27, 720-725 (2008). (Pubitemid 351948583)
68. Tibaldi C, Giovannetti E, Vasile E et al.: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14, 1797 - 1803 (2008).
69. Yonemori K, Ueno H, Okusaka T et al.: Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res. 11, 2620-2624 (2005). (Pubitemid 40569462)
70. Sugiyama E, Kaniwa N, Kim SR et al.: Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25, 32-42 (2007). (Pubitemid 350003048)
71. Ueno H, Kaniwa N, Okusaka T et al.: Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br. J. Cancer 100, 870-873 (2009).
72. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE: Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet. 119, 276-283 (2006).
73. Mahlknecht U, Dransfeld CL, Bulut N et al.: SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia (2009) (Epub ahead of print).
74. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD: Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk. Res. 28, 43-48 (2004). (Pubitemid 37433792)
75. Capizzi RL, White JC, Powell BL, Perrino F: Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin. Hematol. 28, 54-69 (1991).
76. Fridland A, Verhoef V: Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. Semin. Oncol. 14, 262-268 (1987).
77. Liliemark JO, Plunkett W: Regulation of 1-β-D- arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res. 46, 1079-1083 (1986).
78. Bierau J, Van Gennip AH, Leen R, Helleman J, Caron HN, Van Kuilenburg AB: Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity. Int. J. Cancer 103, 387-392 (2003). (Pubitemid 36076432)
79. Verschuur AC, Brinkman J, Van Gennip AH et al.: Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line. Leuk. Res. 25, 891-900 (2001). (Pubitemid 32776580)
80. Verschuur AC, Van Gennip AH, Leen R, Voute PA, Brinkman J, Van Kuilenburg AB: Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-β-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line. Int. J. Cancer 98, 616-623 (2002). (Pubitemid 34208565)
81. Verschuur AC, van Gennip AH, Leen R, Voute PA, van Kuilenburg AB: Cyclopentenyl cytosine increases the phosphorylation and incorporation into dna of arabinofu-ranosyl cytosine in a myeloid leukemic cell-line. Adv. Exp. Med. Biol. 486, 311-317 (2000). ■ The role of CTPS in cellular response of myeloid leukemia cell line to ara-C was investigated. (Pubitemid 32179318)
82. Bierau J, van Gennip AH, Leen R, Meinsma R, Caron HN, van Kuilenburg AB: Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. Cancer Chemother. Pharmacol. 57, 105-113 (2006).
83. Whelan J, Phear G, Yamauchi M, Meuth M: Clustered base substitutions in CTP synthetase conferring drug resistance in Chinese hamster ovary cells. Nat. Genet. 3, 317-322 (1993). (Pubitemid 23112956)
84. Whelan J, Smith T, Phear G, Rohatiner A, Lister A, Meuth M: Resistance to cytosine arabinoside in acute leukemia: the significance of mutations in CTP synthetase. Leukemia 8, 264-265 (1994). (Pubitemid 24057540)
85. Shao J, Zhou B, Chu B, Yen Y: Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6, 409-431 (2006). (Pubitemid 44033390)
86. Chabner BA, Hande KR, Drake JC: Ara-C metabolism: implications for drug resistance and drug interactions. Bull. Cancer 66, 89-92 (1979).
87. Chiba P, Tihan T, Szekeres T et al.: Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia 4, 761-765 (1990). (Pubitemid 20385401)
88. Tattersall MH, Ganeshaguru K, Hoffbrand AV: Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br. J. Haematol. 27, 39-46 (2006).
89. Meuth, M: The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp. Cell Res. 181, 305-316 (1989).
90. Avramis VI, Nandy P, Kwock R et al.: Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res. 18, 2327-2338 (1998). (Pubitemid 28386516)
91. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W: Minimum dose of fludarabine for the maximal modulation of 1-β-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin. Cancer Res. 3, 1539-1545 (1997). (Pubitemid 27431561)
92. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W: Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony- stimulating factor during therapy of acute myelogenous leukemia. Clin. Cancer Res. 1, 169-178 (1995).
93. Gandhi V, Kemena A, Keating MJ, Plunkett W: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 52, 897-903 (1992).
94. Sigmond J, Kamphuis JA, Laan AC, Hoebe EK, Bergman AM, Peters GJ: The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem. Pharmacol. 73, 1548-1557 (2007). (Pubitemid 46527545)
95. Nakahira S, Nakamori S, Tsujie M et al.: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120, 1355-1363 (2007). (Pubitemid 46256791)
96. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64, 3761-3766 (2004). (Pubitemid 38697284)
97. Rosell R, Danenberg KD, Alberola V et al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318-1325 (2004). (Pubitemid 38365223)
98. Bergman AM, Eijk PP, Ruiz vHV et al.: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 65, 9510-9516 (2005).
99. Kwon WS, Rha SY, Choi YH et al.: Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics 16, 429-438 (2006).
100. Kim SO, Jeong JY, Kim MR et al.: Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin. Cancer Res. 14, 3083-3088 (2008).
101. Rha SY, Jeung HC, Choi YH et al.: An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 12, 622-630 (2007).
102. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 69, 178-184 (2009).
103. Guo Y, Kock K, Ritter CA et al.: Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin. Cancer Res. 15, 1762-1769 (2009).
104. Li L, Fridley B, Kalari K et al.: Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68, 7050-7058 (2008). ■ First genome-wide study to screen for association of gene expression with cellular cytotoxicity to gemcitabine and ara-C, and identified NT5C3 and FKBP5 as potential candidate genes.
105. Hartford CM, Duan S, Delaney SM et al.: Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113, 2145-2153 (2009). ■ Study comparing ara-C cellular cytotoxicity of HapMap cell lines with genome-wide genotype and gene expression data.
106. Takagaki K, Katsuma S, Horio T et al.: cDNA microarray analysis of altered gene expression in Ara-C-treated leukemia cells. Biochem. Biophys. Res. Commun. 309, 351-358 (2003). (Pubitemid 37025899)
107. Abe S, Funato T, Takahashi S et al.: Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J. Exp. Med. 209, 217-228 (2006). (Pubitemid 43905553)
108. Yin B, Kogan SC, Dickins RA, Lowe SW, Largaespada DA: Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp. Hematol. 34, 631-641 (2006).
109. Yin B, Tsai ML, Hasz DE, Rathe SK, Le Beau MM, Largaespada DA: A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia 21, 1093-1097 (2007). (Pubitemid 46672088)
110. International HapMap Project www.hapmap.org